News articles about DarioHealth (NASDAQ:DRIO) have trended somewhat positive on Tuesday, according to Accern Sentiment. The research group scores the sentiment of media coverage by analyzing more than 20 million news and blog sources in real time. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. DarioHealth earned a news impact score of 0.17 on Accern’s scale. Accern also assigned news coverage about the company an impact score of 44.5215569810285 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the next few days.
Shares of DarioHealth (NASDAQ DRIO) opened at $1.57 on Tuesday. The company has a market cap of $16.25, a PE ratio of -1.27 and a beta of -1.90. DarioHealth has a 1 year low of $1.33 and a 1 year high of $4.70.
Separately, Aegis reissued a “buy” rating on shares of DarioHealth in a research report on Friday, December 8th.
DarioHealth Corp, formerly Labstyle Innovations Corp, is a digital health (mHealth) company. The Company is engaged in developing and commercializing a technology providing consumers with laboratory-testing capabilities using smart phones and other mobile devices. The Company’s product, Dario, also known as Dario Smart Diabetes Management Solution, is a mobile, real-time, cloud-based, diabetes management solution based on a software application combined with a pocket-sized, blood glucose monitoring device, Dario Smart Meter.
What are top analysts saying about DarioHealth? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for DarioHealth and related companies.